Dr. Reddy’s plans June 5 investor group meeting
Dr. Reddy’s Laboratories Limited has notified exchanges that its management will participate in an investor conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Dr. Reddy’s Laboratories Limited has notified exchanges that its management will participate in an investor conference. The meeting is scheduled for June 5, 2026, organized by Bank of America in Hyderabad as an in-person group meeting from 08:00 to 09:00 IST. The company notes that this schedule may change if needed by either the investors or the company. This update is provided as an information-only disclosure on the company’s investor relations activities.
Key Figures
Key Terms
Regulation 30 regulatory
SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regulatory
analyst / institutional investor meetings financial
group meet financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Dr. Reddy’s Laboratories (RDY) announce in this 6-K filing?
When is Dr. Reddy’s (RDY) scheduled analyst and institutional investor meeting?
Who is organizing Dr. Reddy’s (RDY) June 5, 2026 investor conference?
What is the nature and mode of Dr. Reddy’s (RDY) upcoming investor meeting?
Why did Dr. Reddy’s (RDY) disclose this investor meeting under SEBI Regulation 30?
AI-generated analysis. How Rhea-AI works. Not financial advice.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
June, 2026
Commission File Number 1-15182
DR. REDDY’S LABORATORIES LIMITED
(Translation of registrant’s name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No x
If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.
EXHIBITS
Exhibit |
| Description of Exhibits |
| ||
99.1 | Intimation dated June 1, 2026 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| DR. REDDY’S LABORATORIES LIMITED (Registrant) | ||
|
|
| |
Date: June 1, 2026 | By: | /s/ K Randhir Singh | |
| Name: | K Randhir Singh | |
| Title: | Company Secretary | |
Exhibit 99.1
| Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India
CIN: L85195TG1984PLC004507
Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 Email: mail@drreddys.com Web: www.drreddys.com |
June 1, 2026
National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)
BSE Limited (Scrip Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd. (Stock Code: DRREDDY)
Dear Sir/Madam,
Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Schedule of Analyst / Institutional Investor Meetings
This is to inform that the Company’s management will be participating in the following investor conference with single institution(s)/ investor groups:
Date | Organized by | Location | Meeting mode | Nature of meet | Timing |
05.06.2026 | Bank of America | Hyderabad | In-Person | Group Meet | 08:00 - 09:00 IST |
Please note that the schedule of the aforesaid meeting is subject to change due to any exigencies on the part of Investors / Company.
This is for your information.
Thanking you.
Yours faithfully,
For Dr. Reddy’s Laboratories Limited
K Randhir Singh
Company Secretary, Compliance Officer & Head-CSR